Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,610.06
    -1,573.93 (-3.14%)
     

  • CMC Crypto 200

    1,259.69
    -98.32 (-7.24%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Valeant psoriasis drug safety challenging to assess -FDA Staff

Reuters - UK Focus

July 15 (Reuters) - Valeant Pharmaceuticals International (NYSE: VRX - news) Inc's experimental drug to treat the skin disorder psoriasis carries several potential risks that are challenging to assess due to limited controlled data, a preliminary review by the U.S (Other OTC: UBGXF - news) . Food and Drug Administration.

The review comes two days ahead of a meeting of outside experts who will advise the FDA on whether the drug should be approved. The agency is not obliged to follow the advice of its advisory panels but typically does so.

Some patients in clinical trials committed suicide and the agency said no risk management strategy will completely eliminate the risk of suicide and suicidal thoughts seen with the drug, broadalumab. (Reporting by Toni Clarke in Washington)